Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk of TB with Tofacitinib in SpA
NCT03504072Phase 4Unknown
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jan 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tofacitinib in spondyloarthritis (SpA), sponsored by Bangabandhu Sheikh Mujib Medical University. Status: unknown.
02
Drugs
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on NCT03504072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504072.